IV Secukinumab Trials Hit Primary Endpoints in PsA, AxSpA

Source link : https://www.newshealth.biz/health-news/iv-secukinumab-trials-hit-primary-endpoints-in-psa-axspa/

SAN DIEGO — Monthly use of intravenously administered secukinumab (Cosentyx) proved its efficacy over placebo in treating psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in two industry-sponsored, randomized, double-blinded, phase 3 trials of the drug’s second and newly approved route of administration. The studies of the human monoclonal antibody secukinumab, an interleukin-17 inhibitor, were presented at […]

Author : News Health

Publish date : 2023-11-20 23:52:42

Copyright for syndicated content belongs to the linked Source.